Evidence map›Paper›PMID 38352574›Full record

ArticlebioRxiv : the preprint server for biology2024

The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma.

Lucy Van Kleunen, Mansooreh Ahmadian, Miriam D Post, Rebecca J Wolsky, Christian Rickert, Kimberly Jordan, Junxiao Hu, Jennifer K Richer, Nicole A Marjon, Kian Behbakht and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Lucy Van KleunenDepartment of Computer Science, University of Colorado, Boulder, USA.
Mansooreh AhmadianDepartment of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Miriam D PostDepartment of Pathology, The University of Colorado Anschutz Medical Campus.
Rebecca J WolskyDepartment of Pathology, The University of Colorado Anschutz Medical Campus.
Christian RickertDepartment of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus.
Kimberly JordanDepartment of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus.
Junxiao HuDepartment of Pediatrics, Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, CO, USA.
Jennifer K RicherDepartment of Pathology, The University of Colorado Anschutz Medical Campus.
Nicole A MarjonDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus.
Kian BehbakhtDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus.
Matthew J SikoraDepartment of Pathology, The University of Colorado Anschutz Medical Campus.ORCID 0000-0003-2915-7442
Benjamin G BitlerDepartment of OB/GYN, The University of Colorado Anschutz Medical Campus.
Aaron ClausetDepartment of Computer Science, University of Colorado, Boulder, USA.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
COLORADO WRHR CAREER DEVELOPMENT CENTERK12HD001271 · NICHD · UNIVERSITY OF COLORADO DENVER · PI Saketh R Guntupalli · 1999 to 2026
$8.9M
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparitiesR01CA285446 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler, Matthew J Sikora · 2023 to 2026
$2.4M
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler · 2021 to 2026
$2.4M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA285446NCI NIH HHS R37 CA261987NICHD NIH HHS K12 HD001271
6 · The paper itself

Abstract

Despite ovarian cancer being the deadliest gynecological malignancy, there has been little change to therapeutic options and mortality rates over the last three decades. Recent studies indicate that the composition of the tumor immune microenvironment (TIME) influences patient outcomes but are limited by a lack of spatial understanding. We performed multiplexed ion beam imaging (MIBI) on 83 human high-grade serous carcinoma tumors - one of the largest protein-based, spatially-intact, single-cell resolution tumor datasets assembled - and used statistical and machine learning approaches to connect features of the TIME spatial organization to patient outcomes. Along with traditional clinical/immunohistochemical attributes and indicators of TIME composition, we found that several features of TIME spatial organization had significant univariate correlations and/or high relative importance in high-dimensional predictive models. The top performing predictive model for patient progression-free survival (PFS) used a combination of TIME composition and spatial features. Results demonstrate the importance of spatial structure in understanding how the TIME contributes to treatment outcomes. Furthermore, the present study provides a generalizable roadmap for spatial analyses of the TIME in ovarian cancer research.

Identifiers

PMID38352574
PMCPMC10862769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.